CJC-1295 (with DAC) is a synthetic peptide designed to mimic the activity of endogenous growth hormone-releasing hormone (GHRH), modified with a Drug Affinity Complex (DAC) to enhance stability and prolong activity in controlled laboratory environments. This extended activity profile makes it suitable for research focused on sustained receptor interaction and long-duration signaling dynamics.

In preclinical and in vitro studies, CJC-1295 (with DAC) has been examined for its interaction with GHRH receptors and its role in modulating growth hormone signaling pathways over extended periods. Researchers have explored its effects on receptor binding affinity, intracellular signaling cascades, and endocrine system response mechanisms within experimental models. These investigations remain limited to laboratory and experimental conditions, and further research is required to fully understand its mechanisms and broader implications.

CJC-1295 (with DAC) is frequently associated with research topics such as sustained peptide signaling, endocrine pathway analysis, growth hormone receptor studies, and laboratory-grade synthetic peptides, making it relevant for scientific supply catalogs and research-focused platforms.

This material is supplied exclusively for research and laboratory use. It is not approved by the U.S. Food and Drug Administration for any therapeutic or clinical applications. This product is not intended to diagnose, treat, cure, or prevent any disease and must not be used for human or veterinary consumption.

All handling should be conducted by qualified professionals in appropriate research facilities, following applicable regulatory and safety standards.